RET and adenocarcinoma: Seventeen studies aimed at predicting EGFR status [54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70], one aimed at predicting ALK status [71], three at predicting both EGFR and KRAS status [72,73,74], one at identifying ALK/ROS1/RET fusion-positive versus fusion-negative adenocarcinomas [75] and two at predicting the PD-L1 expression level [76,77].